PATIENT ALERT: Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. Thank you. CLICK HERE for more details​​​​​​. For more information on the nationwide shortage of two platinum-based anticancer drugs, CLICK HERE.

Clinical Research & Trials

Available Trials at VOA in Hampton Roads and Eastern North Carolina

Throughout the last century, the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. Virginia Oncology Associates' physicians have embraced clinical cancer research as a critical component of community-based oncology care. Through a partnership with Duke University Oncology Consortium, National Cancer Institute, and Sarah Cannon Research Institute (SCRI), a joint venture with US Oncology Research, VOA physicians are able to provide cancer patients with innovative treatment options and therapies and clinical trial resources. Virginia Oncology Associates offers the largest clinical research program in all of Hampton Roads and Eastern North Carolina. You do not have to leave the area to receive premier cancer care and the latest cancer treatments.

If you are interested in learning more about our cancer research program, you can read frequently asked questions answered by the clinical trial specialists at Virginia Oncology Associates. You can also call our Research Department at a VOA clinical trial location in the area closest to you:

Peninsula: (757) 873-9400

  • Hampton
  • Newport News
  • Williamsburg

Southside: (757) 466-8683

  • Norfolk
  • Virginia Beach

Breast Cancer Research

  • USO 23009

    A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC699 in Patients with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (AC699-001)

    Available at 1 location

    View Details

  • USO 22159

    A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

    Available at 6 locations

    View Details

  • USO 21507

    A Phase III, Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent, Inoperable or Metastatic Triple-negative Breast Cancer D926PC00001: (TROPION Breast02).

    Available at 4 locations

    View Details

  • USO 22101

    EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

    Available at 5 locations

    View Details

  • USO 22018

    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy And Safety Of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus In Patients With Estrogen Receptor (Er)-Positive, Her2-Negative, Locally Advanced Or Metastatic Breast Cancer (Ml43171)

    Available at 3 locations

    View Details

  • USO 21455

    A Phase Iii,Randomized, Open-Label Study Evaluating The Efficacy And Safety Of Giredestrant In Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo+Taxane In Patients With Previously Untreated Her2-Positive, Estrogen Receptor-Positive Locally-Advanced Or Metastatic Breast Cancer (Wo43571)

    Available at 1 location

    View Details

  • USO 21537

    A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician¡¯s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)

    Available at 4 locations

    View Details

  • USO 21536

    A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 (GS-US-592-6173)

    Available at 4 locations

    View Details

  • USO 20210

    Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

    Available at 4 locations

    View Details

  • USO 21173

    A Phase 3, double-blind, randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

    Available at 1 location

    View Details

  • uso 20408

    A Phase Ill, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor - Positive, Her2‑Negative Early Breast Cancer (Go42784)

    Available at 5 locations

    View Details

  • USO 20396

    Available Locations Critical Document Checklist SAE List my Site 20396 Patients Training Log Generate Document(Florence) my Site 20396 Training Monitoring Calendar CRF Summary A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) (D967UC00001)

    Available at 5 locations

    View Details

  • D9673C00007 (DESTINY-Breast12)

    “An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer(DESTINY-Breast12)”

    Available at 1 location

    View Details

GYN Cancer Research

  • USO 22201

    IMGN853-0421: Randomized, Multicenter, Open-Label, Phase 3 Study Of Mirvetuximab Soravtansine In Combination With Bevacizumab Versus Bevacizumab Alone As Maintenance Therapy For Patients With Folate Receptor Alpha-Positive Recurrent Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-Based Chemotherapy Plus Bevacizumab (IMGN853-0421 GOG-3078)

    Available at 2 locations

    View Details

  • USO 22200

    A PHASE II, SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER (CO44195)

    Available at 2 locations

    View Details

  • USO 22056

    A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

    Available at 2 locations

    View Details

  • USO 20398

    A Phase II, Open-Label, Multicenter, Platform Study Evaluating The Efficacy And Safety Of Biomarker-Driven Therapies In Patients With Persistent Or Recurrent Rare Epithelial Ovarian Tumors (Wo42178/Engot-Gyn2/Gog-3051)

    Available at 2 locations

    View Details

Gastrointestinal Cancer Research

  • uso 21326

    A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102 (20210098))

    Available at 1 location

    View Details

Genitourinary Cancer Research

  • USO 21546

    TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor (AV-951-20-304)

    Available at 5 locations

    View Details

  • uso 21207

    (PSMAddition): An international Prospective Open-label, Randomized, Phase III Study comparing [177Lu]Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)(CAAA617C12301)

    Available at 2 locations

    View Details

  • USO 20403

    A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer D910PC00001:(VOLGA)

    Available at 1 location

    View Details

  • USO 18283

    A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)

    Available at 2 locations

    View Details

Hematology

  • USO 20219

    A Dual-Cohort, Open-Label, Phase 2 Study Of Brentuximab Vedotin And CHP (A+CHP) In The Frontline Treatment Of Subjects With Peripheral T-Cell Lymphoma (PTCL) With Less Than 10% CD30 Expression (SGN35-032)

    Available at 5 locations

    View Details

Lung Cancer Research

  • USO 22269

    A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

    Available at 6 locations

    View Details

  • USO 22285

    Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

    Available at 6 locations

    View Details

Multiple Myeloma

  • USO 23031

    A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients (64007957MMY2010)

    Available at 1 location

    View Details

Solid Tumors Research

  • USO 22166

    Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01)

    Available at 1 location

    View Details

  • USO 20283

    A Phase 2 Study Of Brentuximab Vedotin In Combination With Pembrolizumab In Subjects With Metastatic Solid Malignancies After Progression On Prior PD-1 Inhibitor Treatment (SGN35-033)

    Available at 4 locations

    View Details

  • USO 19151

    A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) STAR

    Available at 1 location

    View Details

Lymphoma & Hematologic

  • USO 21550

    A Phase II multi-center, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

    Available at 5 locations

    View Details

  • USO 22033

    A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

    Available at 2 locations

    View Details

Cellular & Gene

  • uso 21412

    A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma (FT576-101)

    Available at 1 location

    View Details

Tissue Collection

  • USO 22311

    Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

    Available at 6 locations

    View Details